Skip to main content
SpringerLink
Log in

Incorporating biomarkers into clinical trial designs: points to consider

  • Commentary
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

In an environment where the regulatory and reimbursement authorities continue to raise the bar for new oncology therapies, how are sponsors adapting clinical trial designs?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. Regulatory Innovation. BioCentury 39, A1–A28, September 13, 2010.

  2. Jallal, B. Euro. Pharm. Rev. 16, 29–31 (2011).

    Google Scholar 

  3. LaVallee, T. Onc. News. 6, 52 (2011).

    Google Scholar 

  4. Heinemann, V. et al. Cancer Treat. Rev. 35, 262–271 (2009).

    Article  CAS  Google Scholar 

  5. Beckman, R.A. et al. Nat. Rev. Drug Discov. 10, 735–748 (2011).

    Article  CAS  Google Scholar 

  6. Sikorski, R. & Yao, B. Sci. Transl. Med. 1, 10ps11 (2009).

    Article  Google Scholar 

  7. Barker, A.D. et al. Clin. Pharmacol. Ther. 86, 97–100 (2009).

    Article  CAS  Google Scholar 

  8. Fleming, T. & Richardson, B.A. J. Infect. Dis. 190, 666–674 (2004).

    Article  CAS  Google Scholar 

  9. Patlak, M., Nass, S.J. & Balogh, E. The National Cancer Policy Summit: Opportunities and Challenges in Cancer Research and Care. http://books.nap.edu/openbook.php?record_id=13101 (The National Academies Press, Washington, DC, 2011).

    Book  Google Scholar 

  10. D'Agostino, R.B. N. Engl. J. Med., 365, e2 (2011).

    Article  CAS  Google Scholar 

  11. Chen, K. & Shan, M. Contemp. Clin. Trials 29, 32–41 (2008).

    Article  Google Scholar 

  12. Vickers, A.J., Ballen, V. & Scher, H.I. Clin. Cancer Res. 13, 972–976 (2007).

    Article  Google Scholar 

  13. Thall, P.F. UT MD Anderson Cancer Center Department of Biostatistics Working Paper Series http://biostats.bepress.com/mdandersonbiostat/paper35/ (2007).

    Google Scholar 

  14. Robert, C. et al. N. Engl. J. Med. 364, 2517–2526 (2011).

    Article  CAS  Google Scholar 

  15. Maitland, M. et al. J. Clin. Oncol. 29, 3109–3111 (2011).

    Article  Google Scholar 

  16. Hoos, A. et al. J. Natl. Cancer Inst. 102, 1388–1397 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Edward Bradley is therapeutic head and vice president, Clinical Development, Oncology, MedImmune, Gaithersburg, Maryland, USA.,

    Edward Bradley

Authors
  1. Edward Bradley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward Bradley.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bradley, E. Incorporating biomarkers into clinical trial designs: points to consider. Nat Biotechnol 30, 596–599 (2012). https://doi.org/10.1038/nbt.2296

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2296

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation